Literature DB >> 2014797

A murine model for type III tyrosinemia: lack of immunologically detectable 4-hydroxyphenylpyruvic acid dioxygenase enzyme protein in a novel mouse strain with hypertyrosinemia.

F Endo1, H Katoh, S Yamamoto, I Matsuda.   

Abstract

We have characterized a new mutant strain of mouse that has hypertyrosinemia. The blood tyrosine level was persistently high, and increased amounts of 4-hydroxyphenylpyruvic acid and its derivatives were excreted into the urine. Succinylacetone was not detected in urine samples from these mice. All the animals were apparently healthy, and there was no evidence of hepatorenal dysfunction. The hypertyrosinemia was transmitted through an autosomal recessive inheritance. Analyses of hepatic enzymes related to tyrosine metabolism revealed that 4-hydroxyphenylpyruvic acid dioxygenase activity was virtually absent, while fumarylacetoacetase and tyrosine aminotransferases (cytosolic and mitochondrial forms) were normal in these mutant mice. Immunoblot analysis of 4-hydroxyphenylpyruvic acid dioxygenase protein in the liver indicated that the subunit protein of the enzyme was absent. It would appear that hypertyrosinemia in this mutant strain was caused by a genetic defect in 4-hydroxyphenylpyruvic acid dioxygenase. These features are similar to type III tyrosinemia in humans. Analysis of this mutant strain of mouse is expected to provide valuable information on the pathogenesis of human type III tyrosinemia and can also serve as a useful system for studies on tyrosine metabolism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2014797      PMCID: PMC1682955     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  18 in total

1.  Purification and some properties of human 4-hydroxyphenylpyruvate dioxygenase (I).

Authors:  B Lindblad; G Lindstedt; S Lindstedt; M Rundgren
Journal:  J Biol Chem       Date:  1977-07-25       Impact factor: 5.157

2.  Abnormal ornithine carbamoyltransferase in mice having the sparse-fur mutation.

Authors:  R DeMars; S L LeVan; B L Trend; L B Russell
Journal:  Proc Natl Acad Sci U S A       Date:  1976-05       Impact factor: 11.205

3.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

4.  The enzymatic deficiency in tyrosinemia.

Authors:  B N La Du
Journal:  Am J Dis Child       Date:  1967-01

5.  Radiochemical assays for p-hydroxyphenylpyruvate hydroxylase activity in human liver.

Authors:  B Lindblad
Journal:  Clin Chim Acta       Date:  1971-08       Impact factor: 3.786

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Purification and properties of avian liver p-hydroxyphenylpyruvate hydroxylase.

Authors:  G H Wada; J H Fellman; T S Fujita; E S Roth
Journal:  J Biol Chem       Date:  1975-09-10       Impact factor: 5.157

8.  Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia.

Authors:  R Berger; G P Smit; S A Stoker-de Vries; M Duran; D Ketting; S K Wadman
Journal:  Clin Chim Acta       Date:  1981-07-18       Impact factor: 3.786

9.  Assay of fumarylacetoacetate fumarylhydrolase in human liver-deficient activity in a case of hereditary tyrosinemia.

Authors:  E A Kvittingen; E Jellum; O Stokke
Journal:  Clin Chim Acta       Date:  1981-09       Impact factor: 3.786

10.  Gas-chromatographic method of analysis for urinary organic acids. I. Retention indices of 155 metabolically important compounds.

Authors:  K Tanaka; D G Hine; A West-Dull; T B Lynn
Journal:  Clin Chem       Date:  1980-12       Impact factor: 8.327

View more
  7 in total

1.  Tissue-specific FAH deficiency alters sleep-wake patterns and results in chronic tyrosinemia in mice.

Authors:  Shuzhang Yang; Sandra M Siepka; Kimberly H Cox; Vivek Kumar; Marleen de Groot; Yogarany Chelliah; Jun Chen; Benjamin Tu; Joseph S Takahashi
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

2.  Tyrosinaemia type III: immunochemical studies on 4-hydroxyphenylpyruvic acid dioxygenase and molecular cloning of cDNA for the enzyme.

Authors:  F Endo; H Awata; A Tanoue; Y Eda; I Matsuda
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

3.  Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome.

Authors:  S Miyake; M Makimura; Y Kanegae; S Harada; Y Sato; K Takamori; C Tokuda; I Saito
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-06       Impact factor: 11.205

4.  Benign tyrosinaemia: an 18-year follow-up.

Authors:  G Stoppoloni; R Santinelli; F Prisco; G Canino; D Iafusco; F Di Palma
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

Review 5.  Tyrosinaemia type I and apoptosis of hepatocytes and renal tubular cells.

Authors:  F Endo; M S Sun
Journal:  J Inherit Metab Dis       Date:  2002-05       Impact factor: 4.982

6.  Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors.

Authors:  S Kubo; M Sun; M Miyahara; K Umeyama; K Urakami; T Yamamoto; C Jakobs; I Matsuda; F Endo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

7.  HPD degradation regulated by the TTC36-STK33-PELI1 signaling axis induces tyrosinemia and neurological damage.

Authors:  Yajun Xie; Xiaoyan Lv; Dongsheng Ni; Jianing Liu; Yanxia Hu; Yamin Liu; Yunhong Liu; Rui Liu; Hui Zhao; Zhimin Lu; Qin Zhou
Journal:  Nat Commun       Date:  2019-09-19       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.